OMEGAPHARM PIPERACILLIN AND TAZOBACTAM FOR INJECTION 2 g/0.25 g piperacillin 2g (as sodium) and tazobactam 250mg (as sodium) pow

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

piperacillin sodium, Quantity: 2085 mg (Equivalent: piperacillin, Qty 2000 mg); tazobactam sodium, Quantity: 268 mg (Equivalent: tazobactam, Qty 250 mg)

Available from:

Omegapharm

INN (International Name):

piperacillin sodium,tazobactam sodium

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients:

Administration route:

Intravenous

Units in package:

1 vial, 5 vials

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

OMEGAPHARM PIPERACILLIN AND TAZOBACTAM is indicated for the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the following conditions, - lower respiratory tract infections, - urinary tract infections (complicated and uncomplicated), - intra-abdominal infections, - skin and skin structure infections, - bacterial septicaemia, and, - gynaecological infections. Children under the age of 12 years. In hospitalised children aged 2 to 12 years, OMEGAPHARM PIPERACILLIN AND TAZOBACTAM is indicated for the treatment of serious intra-abdominal infections. It has not been evaluated in this indication for paediatric patients below the age of 2 years. . While OMEGAPHARM PIPERACILLIN AND TAZOBACTAM is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. Appropriate culture and susceptibility tests sho

Product summary:

Visual Identification: White or off-white powder.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Registered

Authorization date:

2011-09-08